We pioneer the future of health through advanced biotechnology — targeting the root causes of aging and neurodegeneration. Our mission is to transform how we age by developing well-aging solutions and therapeutics for neurodegenerative diseases, enabling individuals to live longer, healthier, and cognitively vibrant lives.
2025
Based in Daedeok Special R&D Innopolis, Daejeon, South Korea
Introduction
Our journey began not with a company, but with a discovery — a breakthrough that laid the foundation for everything ThanEver stands for today.
Step 1
The Discovery
At the University of Pennsylvania, our scientific advisor isolated neural stem cells — a landmark published in Nature Science, and a cornerstone in the field of regenerative neuroscience.
Step 2
The Innovation
Building on that legacy, our founding research team developed gene-encoded stem cell cultures capable of modeling neurodegenerative diseases at the University of British Columbia, Canada.
Step 3
The Breakthrough
We advanced the field with the world’s most sophisticated exosome platform, uniquely designed to penetrate the blood-brain barrier (BBB) — opening new doors in central nervous system (CNS) therapeutics.
Step 4
The Mission Begins
In 2025, ThanEver was founded to bring 40 years of neuroscience out of the lab — and into lives. With Smartsome™, we launched the first exosome platform designed for cognitive longevity, opening new clinical paths for brain health, functional aging, and scalable neurorestoration. From research to real-world application, our mission begins where medicine meets meaning.
ThanEver has filed 3 of its 6 core patents, covering BBB exosome delivery, therapeutic targeting, and companion-animal applications. Our platform is now being applied to both human and companion-animal therapeutics — with early IP protections already underway.
Our programs are designed not just for clinical endpoints, but for real-world translation — with early use cases in companion-animal therapeutics already underway.
